Clinical Trial Update: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure [Phase 3]

View source ↗

Summary

Phase 3 trial comparing D-1553 tablet to docetaxel injection in KRAS G12C mutation-positive non-small cell lung cancer after prior therapy; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• D-1553
• Docetaxel injection (docetaxel)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING